"Life-changing": the experience of super-responders to biologics in severe asthma.
Biologics
Patient perspectives
QoL
Qualitative
Severe asthma
Super-responders
Journal
BMC pulmonary medicine
ISSN: 1471-2466
Titre abrégé: BMC Pulm Med
Pays: England
ID NLM: 100968563
Informations de publication
Date de publication:
28 Nov 2022
28 Nov 2022
Historique:
received:
17
05
2022
accepted:
14
11
2022
entrez:
27
11
2022
pubmed:
28
11
2022
medline:
30
11
2022
Statut:
epublish
Résumé
There is limited information on the patient's perspective of how biologic treatments impact their lives. We conducted a qualitative study to explore the patient's experience of being considered a super-responder from a quality of life perspective. Patients with severe asthma identified as super-responders were invited to semi-structured interviews conducted online. Participants could bring a family member/friend to the interview. The interviews explored experiences of biologic treatment, were transcribed and underwent thematic analysis. Twenty-five participants took part in this study. Themes emerged on the impact of biologic treatment for participants and for their friends/family: (i) Words used to describe their often life-changing experiences and (ii) the positive changes noted. Biologic treatment stopped the disruption of family life and social life caused by exacerbations. Improvements in mental health were also noted. Marked individual variations in the way it affected their lives were noted. Most participants noticed improvements 2-3 months after starting their biologic, but some noticed improvement within a few days and others after 6 months. Super-responders reported profound but heterogeneous improvements following biologic treatment beyond asthma symptoms and exacerbations including important benefits to social and family life. Improvements may be underestimated as social and family benefits are not reliably measured in current studies with implications for health economic evaluations. Not all patients are super-responders, and excellent responses may be lost in group mean data in trials. Individual time course and response patterns need further elucidation to identify who will respond best to biologics.
Sections du résumé
BACKGROUND
BACKGROUND
There is limited information on the patient's perspective of how biologic treatments impact their lives. We conducted a qualitative study to explore the patient's experience of being considered a super-responder from a quality of life perspective.
METHODS
METHODS
Patients with severe asthma identified as super-responders were invited to semi-structured interviews conducted online. Participants could bring a family member/friend to the interview. The interviews explored experiences of biologic treatment, were transcribed and underwent thematic analysis.
RESULTS
RESULTS
Twenty-five participants took part in this study. Themes emerged on the impact of biologic treatment for participants and for their friends/family: (i) Words used to describe their often life-changing experiences and (ii) the positive changes noted. Biologic treatment stopped the disruption of family life and social life caused by exacerbations. Improvements in mental health were also noted. Marked individual variations in the way it affected their lives were noted. Most participants noticed improvements 2-3 months after starting their biologic, but some noticed improvement within a few days and others after 6 months.
CONCLUSIONS
CONCLUSIONS
Super-responders reported profound but heterogeneous improvements following biologic treatment beyond asthma symptoms and exacerbations including important benefits to social and family life. Improvements may be underestimated as social and family benefits are not reliably measured in current studies with implications for health economic evaluations. Not all patients are super-responders, and excellent responses may be lost in group mean data in trials. Individual time course and response patterns need further elucidation to identify who will respond best to biologics.
Identifiants
pubmed: 36437459
doi: 10.1186/s12890-022-02241-2
pii: 10.1186/s12890-022-02241-2
pmc: PMC9702657
doi:
Substances chimiques
Biological Products
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
445Subventions
Organisme : GlaxoSmithKline
ID : Innovations in Severe Asthma grant
Informations de copyright
© 2022. The Author(s).
Références
J Allergy Clin Immunol Pract. 2021 Jul;9(7):2732-2741.e1
pubmed: 33577946
Nurs Forum. 2021 Apr;56(2):421-428
pubmed: 33634534
Front Psychol. 2021 Nov 26;12:788351
pubmed: 34899540
Qual Life Res. 2015 Mar;24(3):631-9
pubmed: 25201169
Cochrane Database Syst Rev. 2017 Sep 21;9:CD010834
pubmed: 28933516
Eur Respir J. 2017 Sep 20;50(3):
pubmed: 28931662
Eur Respir J. 2020 Jan 2;55(1):
pubmed: 31558662
J Asthma. 2022 May;59(5):980-988
pubmed: 33625306
Eur Respir J. 2021 Jun 17;57(6):
pubmed: 33632801
Allergy. 2021 Jan;76(1):14-44
pubmed: 32484954
Eur Respir J. 2018 Jul 11;52(1):
pubmed: 29794132
J Asthma Allergy. 2021 Mar 15;14:245-258
pubmed: 33758515
Eur Respir J. 2017 May 1;49(5):
pubmed: 28461308
Respir Med. 2020 Feb;162:105870
pubmed: 32056677
ERJ Open Res. 2021 Mar 29;7(1):
pubmed: 33816596
Health Qual Life Outcomes. 2018 Jan 27;16(1):24
pubmed: 29374455
ERJ Open Res. 2021 Apr 06;7(2):
pubmed: 33834052
Eur Respir J. 2014 Feb;43(2):343-73
pubmed: 24337046
Eur Respir J. 2016 Feb;47(2):410-9
pubmed: 26828055
J Allergy Clin Immunol Pract. 2021 Nov;9(11):3997-4004
pubmed: 34271216
J Allergy Clin Immunol. 2020 Mar;145(3):757-765
pubmed: 31866436
Eur Respir J. 2022 Sep 14;:
pubmed: 36104293
Cochrane Database Syst Rev. 2014 Jan 13;(1):CD003559
pubmed: 24414989